| Name | Title | Contact Details |
|---|
OrthoTennessee provides the finest orthopedic clinics in East Tennessee, improving lives through patient-centered care, orthotics, therapy and imaging.
Leader in the manufacture of generic drugs, we produce and distribute brand name drugs and over-the-counter drugs. Based in Montreal, Canada, we have about 1 500 employees. Our products are sold in more than sixty countries. Our portfolio of 340 products cumulates 2000 different dosage strengths. We invest $ 30 million per year in research and development. We firmly believe that we must be an example in our community. We support many charities, here as elsewhere. For international humanitarian purposes, we have donated products valued at approximately $ 23.5 million over the past five years.
We are a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker`s cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets. Once infused into patients, this population of T cells attacks multiple tumor targets and acts to activate the patient`s immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cells, when compared to current engineered CAR-T and TCR-based approaches, its products (i) are significantly less expensive and easier to manufacture, (ii) appear to be markedly less toxic, and (iii) are associated with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling therapeutic product profile, as compared to current gene-modified CAR-T and TCR-based therapies. Marker is also advancing a number of innovative peptide- and gene-based immuno-therapeutics for the treatment of cancer and metastatic disease, including our Folate Receptor Alpha program (TPIV200) for breast and ovarian cancers and our HER2/neu+ peptide antigen program (TPIV100/110) in Phase II clinical trials. In parallel, we are developing a proprietary DNA expression technology named PolyStart™ to improve the ability of the cellular immune system to recognize and destroy diseased cells.
Octamer is a Belvedere Tiburon, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.